These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients. Massip C; Mathieu C; Gaudru C; Miaut V; Floch P; Oswald E; Segonds C; Guet-Revillet H J Antimicrob Chemother; 2019 Feb; 74(2):525-528. PubMed ID: 30312409 [No Abstract] [Full Text] [Related]
3. "Switching Partners": Piperacillin-Avibactam Is a Highly Potent Combination against Multidrug-Resistant Zeiser ET; Becka SA; Wilson BM; Barnes MD; LiPuma JJ; Papp-Wallace KM J Clin Microbiol; 2019 Aug; 57(8):. PubMed ID: 31167848 [TBL] [Abstract][Full Text] [Related]
4. Van Dalem A; Herpol M; Echahidi F; Peeters C; Wybo I; De Wachter E; Vandamme P; Piérard D Antimicrob Agents Chemother; 2018 Sep; 62(9):. PubMed ID: 29914964 [TBL] [Abstract][Full Text] [Related]
5. Major Aspects of Burkholderia gladioli and Burkholderia cepacia Infections in Children. Bedir Demirdag T; Ozkaya Parlakay A; Aygar IS; Gulhan B; Kanik Yuksek S Pediatr Infect Dis J; 2020 May; 39(5):374-378. PubMed ID: 32118858 [TBL] [Abstract][Full Text] [Related]
6. Antimicrobial activity of ceftolozane/tazobactam tested against Pseudomonas aeruginosa and Enterobacteriaceae with various resistance patterns isolated in European hospitals (2011-12). Sader HS; Farrell DJ; Castanheira M; Flamm RK; Jones RN J Antimicrob Chemother; 2014 Oct; 69(10):2713-22. PubMed ID: 24917579 [TBL] [Abstract][Full Text] [Related]
7. Comment on: In vitro activity of seven β-lactams including ceftolozane/tazobactam and ceftazidime/avibactam against Burkholderia cepacia complex, Burkholderia gladioli and other non-fermentative Gram-negative bacilli isolated from cystic fibrosis patients. Baklouti S; Massip C; Mane C; Guet-Revillet H; Murris M; Concordet D; Gandia P J Antimicrob Chemother; 2019 Oct; 74(10):3122-3123. PubMed ID: 31335940 [No Abstract] [Full Text] [Related]
8. Antimicrobial susceptibility and synergy studies of Burkholderia cepacia complex isolated from patients with cystic fibrosis. Zhou J; Chen Y; Tabibi S; Alba L; Garber E; Saiman L Antimicrob Agents Chemother; 2007 Mar; 51(3):1085-8. PubMed ID: 17158942 [TBL] [Abstract][Full Text] [Related]
9. In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa and Enterobacteriaceae recovered in Spanish medical centres: Results of the CENIT study. Tato M; García-Castillo M; Bofarull AM; Cantón R; Int J Antimicrob Agents; 2015 Nov; 46(5):502-10. PubMed ID: 26315199 [TBL] [Abstract][Full Text] [Related]
10. In vitro antimicrobial activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and other non-fermenting Gram-negative bacteria in adults with cystic fibrosis. Gramegna A; Millar BC; Blasi F; Elborn JS; Downey DG; Moore JE J Glob Antimicrob Resist; 2018 Sep; 14():224-227. PubMed ID: 29559421 [TBL] [Abstract][Full Text] [Related]
11. Novel antibiotic combinations proposed for treatment of El-Halfawy OM; Naguib MM; Valvano MA Antimicrob Resist Infect Control; 2017; 6():120. PubMed ID: 29204272 [TBL] [Abstract][Full Text] [Related]
12. Examining the activity of cefepime-taniborbactam against Mojica MF; Zeiser ET; Becka SA; LiPuma JJ; Six DA; Moeck G; Papp-Wallace KM Antimicrob Agents Chemother; 2023 Nov; 67(11):e0049823. PubMed ID: 37768313 [TBL] [Abstract][Full Text] [Related]
14. Ceftolozane/tazobactam activity against drug-resistant Enterobacteriaceae and Pseudomonas aeruginosa causing healthcare-associated infections in the Asia-Pacific region (minus China, Australia and New Zealand): report from an Antimicrobial Surveillance Programme (2013-2015). Pfaller MA; Shortridge D; Sader HS; Castanheira M; Flamm RK Int J Antimicrob Agents; 2018 Feb; 51(2):181-189. PubMed ID: 28993143 [TBL] [Abstract][Full Text] [Related]
15. Clonality and Antimicrobial Susceptibility of Burkholderia cepacia complex Isolates Collected from Cystic Fibrosis Patients during 1998-2013 in Bern, Switzerland. Lupo A; Isis E; Tinguely R; Endimiani A New Microbiol; 2015 Apr; 38(2):281-8. PubMed ID: 25938755 [TBL] [Abstract][Full Text] [Related]
16. Ceftolozane/tazobactam activity tested against aerobic Gram-negative organisms isolated from intra-abdominal and urinary tract infections in European and United States hospitals (2012). Sader HS; Farrell DJ; Flamm RK; Jones RN J Infect; 2014 Sep; 69(3):266-77. PubMed ID: 24780763 [TBL] [Abstract][Full Text] [Related]
17. Ceftolozane/tazobactam activity tested against Gram-negative bacterial isolates from hospitalised patients with pneumonia in US and European medical centres (2012). Farrell DJ; Sader HS; Flamm RK; Jones RN Int J Antimicrob Agents; 2014 Jun; 43(6):533-9. PubMed ID: 24856078 [TBL] [Abstract][Full Text] [Related]
18. In vitro efficacy of high-dose tobramycin against Burkholderia cepacia complex and Stenotrophomonas maltophilia isolates from cystic fibrosis patients. Ratjen A; Yau Y; Wettlaufer J; Matukas L; Zlosnik JE; Speert DP; LiPuma JJ; Tullis E; Waters V Antimicrob Agents Chemother; 2015 Jan; 59(1):711-3. PubMed ID: 25348526 [TBL] [Abstract][Full Text] [Related]
19. Comparison of antimicrobial activity between ceftolozane-tazobactam and ceftazidime-avibactam against multidrug-resistant isolates of Escherichia coli, Klebsiella pneumoniae, and Pseudomonas aeruginosa. Alatoom A; Elsayed H; Lawlor K; AbdelWareth L; El-Lababidi R; Cardona L; Mooty M; Bonilla MF; Nusair A; Mirza I Int J Infect Dis; 2017 Sep; 62():39-43. PubMed ID: 28610832 [TBL] [Abstract][Full Text] [Related]
20. Microbiological and epidemiological features of clinical respiratory isolates of Burkholderia gladioli. Segonds C; Clavel-Batut P; Thouverez M; Grenet D; Le Coustumier A; Plésiat P; Chabanon G J Clin Microbiol; 2009 May; 47(5):1510-6. PubMed ID: 19297595 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]